Cargando…

The Advantage of Cyclosporine A and Methotrexate Rotational Therapy in Long-Term Systemic Treatment for Chronic Plaque Psoriasis in a Real World Practice

BACKGROUND: Psoriasis is a chronic inflammatory disease. In the treatment of psoriasis, cyclosporine is commonly prescribed systemic agents. However, long-term use of cyclosporine is not recommended because of side effects such as nephrotoxicity or hypertension. OBJECTIVE: To ascertain the improved...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choi, Chong Won, Kim, Bo Ri, Ohn, Jungyoon, Youn, Sang Woong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Dermatological Association; The Korean Society for Investigative Dermatology 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318527/ https://www.ncbi.nlm.nih.gov/pubmed/28223747 http://dx.doi.org/10.5021/ad.2017.29.1.55

Ejemplares similares

Methotrexate in a Real-World Psoriasis Treatment: Is It Really a Dangerous Medication for All?
por: Kim, Bo Ri, et al.
Publicado: (2017)

Risk Factors Affecting Adverse Effects of Cyclosporine A in a Real-World Psoriasis Treatment
por: Kim, Bo Ri, et al.
Publicado: (2018)

Economic Factors as Major Determinants of Ustekinumab Drug Survival of Patients with Chronic Plaque Psoriasis in Korea
por: Choi, Chong Won, et al.
Publicado: (2018)

Real-World Experience with Etanercept Therapy and the Switching Pattern among Korean Patients with Psoriasis after Withdrawal of Etanercept
por: Choi, Chong Won, et al.
Publicado: (2019)

Docetaxel-Aggravated Psoriasis
por: Yang, Seungkeol, et al.
Publicado: (2019)

Efficacy of Methotrexate in patients with plaque type psoriasis
por: Haider, Sabiqa, et al.
Publicado: (2014)

The MARCOPOLO Study of Ustekinumab Utilization and Efficacy in a Real-World Setting: Treatment of Patients with Plaque Psoriasis in Asia-Pacific Countries
por: Youn, Sang Woong, et al.
Publicado: (2016)

Real-world Methotrexate Use in a Prospective Cohort of Paediatric Patients with Plaque Psoriasis: Effectiveness, Adverse Events and Folic Acid Regimen
por: BRUINS, Finola M., et al.
Publicado: (2022)

Acute methotrexate toxicity presenting as ulcers in plaques of psoriasis vulgaris
por: Bhatnagar, Anuj, et al.
Publicado: (2015)

Reduction of Inter-Rater and Intra-Rater Variability in Psoriasis Area and Severity Index Assessment by Photographic Training
por: Youn, Sang Woong, et al.
Publicado: (2015)

A Comparative Study of the Efficacy of Methotrexate versus Methotrexate with Apremilast in Moderate to Severe Chronic Plaque Psoriasis
por: Srivastava, Divyanshu, et al.
Publicado: (2023)

Morphological Characteristics of Psoriatic Lesions Affect the Accuracy and Reliability of Severity Assessments: Proposal for New Working Criteria for the Psoriasis Area and Severity Index
por: Choi, Chong Won, et al.
Publicado: (2019)

Comparative Study of Clinical Characteristics according to Therapeutic Efficacy and Drug Survival of Cyclosporine or Methotrexate in Psoriasis Vulgaris
por: Lee, Hyun Soo, et al.
Publicado: (2019)

Economic Burden Can Be the Major Determining Factor Resulting in Short-Term Intermittent and Repetitive Ustekinumab Treatment for Moderate-to-Severe Psoriasis
por: Choi, Chong Won, et al.
Publicado: (2018)

Real-World Insight on Apremilast Therapy in Patients with Plaque Psoriasis: Indian Experience
por: De, Abhishek, et al.
Publicado: (2020)

Adherence to Topical Therapies for the Treatment of Psoriasis: Surveys of Physicians and Patients
por: Choi, Jee Woong, et al.
Publicado: (2017)

Histopathological Findings Are Associated with the Clinical Types of Psoriasis but Not with the Corresponding Lesional Psoriasis Severity Index
por: Kim, Byung Yoon, et al.
Publicado: (2015)

Effect of cyclosporin on distribution of methotrexate into the brain of rats
por: OGUSHI, Naofumi, et al.
Publicado: (2015)

Both Educational Lectures and Reference Photographs Are Necessary to Improve the Accuracy and Reliability of Psoriasis Area and Severity Index (PASI) Assessment: Results from Korean Nation-Wide PASI Educational Workshop
por: Choi, Chong Won, et al.
Publicado: (2018)

A Real-World Study to Assess the Effectiveness of Itolizumab in Patients with Chronic Plaque Psoriasis
por: Parthasaradhi, Anchala, et al.
Publicado: (2017)

Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis
por: VAN MUIJEN, Marloes E., et al.
Publicado: (2022)

Cyclosporine Regimens in Plaque Psoriasis: An Overview with Special Emphasis on Dose, Duration, and Old and New Treatment Approaches
por: Colombo, M. D., et al.
Publicado: (2013)

Comparative Effectiveness and Safety of Methotrexate Versus PUVA in Severe Chronic Stable Plaque Psoriasis
por: Banerjee, Saikat, et al.
Publicado: (2021)

Use of Methotrexate in the Treatment of Moderate to Severe Plaque Psoriasis in France: A Practice Survey
por: Fougerousse, Anne-Claire, et al.
Publicado: (2021)

Toenail Psoriasis during Ustekinumab Therapy: Results and Limitations
por: Yang, Seungkeol, et al.
Publicado: (2021)

Severe Nail Fold Psoriasis Extending from Nail Psoriasis Resolved with Ustekinumab: Suggestion of a Cytokine Overflow Theory in the Nail Unit
por: Byun, Sang Young, et al.
Publicado: (2016)

Tissue and Serum Inflammatory Cytokine Levels in Korean Psoriasis Patients: A Comparison between Plaque and Guttate Psoriasis
por: Roh, Nam Kyung, et al.
Publicado: (2015)

The Management of Erythrodermic Psoriasis Complicated by Cyclosporine
por: Rao, Suman, et al.
Publicado: (2020)

Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis
por: MÄLKÖNEN, Tarja, et al.
Publicado: (2022)

Methotrexate Toxicity During Treatment of Chronic Plaque Psoriasis: A Case Report and Review of the Literature
por: Weidmann, Anja, et al.
Publicado: (2014)

Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: An analysis of 75 patients in Taiwan
por: Chen, Yu-Chen, et al.
Publicado: (2020)

Dose Adjustment of Biologic Treatments for Moderate-to-Severe Plaque Psoriasis in the Real World: A Systematic Review
por: Gambardella, Alessio, et al.
Publicado: (2021)

Real-world use of dimethyl fumarate in patients with plaque psoriasis: a Delphi-based expert consensus
por: Burlando, Martina, et al.
Publicado: (2022)

Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA)
por: Graier, T., et al.
Publicado: (2022)

Real-World Effectiveness of 9–12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry
por: Armstrong, April W., et al.
Publicado: (2022)

Real-world treatment patterns, patient-reported outcomes, and effectiveness of flexibledosing etanercept in patients with plaque psoriasis in Greece
por: Rigopoulos, Dimitris, et al.
Publicado: (2022)

Treatment satisfaction, safety and effectiveness of adding methotrexate to adalimumab in patients with psoriasis responding suboptimally to adalimumab in a real‐world setting
por: Papp, K.A., et al.
Publicado: (2022)

Methotrexate and Adalimumab Decrease the Serum Levels of Cardiovascular Disease Biomarkers (VCAM-1 and E-Selectin) in Plaque Psoriasis
por: Zdanowska, Natalia, et al.
Publicado: (2020)

Methotrexate, Cyclosporine A, and Biologics Protect against Atherosclerosis in Rheumatoid Arthritis
por: Kisiel, Bartłomiej, et al.
Publicado: (2015)

Guselkumab for plaque psoriasis
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_aj94vgktk2s1madk96tl3hu926